首页> 美国卫生研究院文献>EBioMedicine >The heat shock protein amplifier arimoclomol improves refolding maturation and lysosomal activity of glucocerebrosidase
【2h】

The heat shock protein amplifier arimoclomol improves refolding maturation and lysosomal activity of glucocerebrosidase

机译:热激蛋白放大器阿莫洛莫可改善葡萄糖脑苷脂酶的重折叠成熟和溶酶体活性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundGaucher Disease is caused by mutations of the GBA gene which encodes the lysosomal enzyme acid beta-glucosidase (GCase). GBA mutations commonly affect GCase function by perturbing its protein homeostasis rather than its catalytic activity. Heat shock proteins are well known cytoprotective molecules with functions in protein homeostasis and lysosomal function and their manipulation has been suggested as a potential therapeutic strategy for GD. The investigational drug arimoclomol, which is in phase II/III clinical trials, is a well-characterized HSP amplifier and has been extensively clinically tested. Importantly, arimoclomol efficiently crosses the blood-brain-barrier presenting an opportunity to target the neurological manifestations of GD, which remains without a disease-modifying therapy.
机译:背景高雪氏病是由编码溶酶体酶酸性β-葡萄糖苷酶(GCase)的GBA基因突变引起的。 GBA突变通常通过干扰其蛋白质稳态而不是其催化活性来影响GCase的功能。热休克蛋白是众所周知的细胞保护分子,其具有蛋白质稳态和溶酶体功能,并且已建议将其操纵作为GD的潜在治疗策略。处于II / III期临床试验中的研究药物阿莫洛莫是一种特征明确的HSP放大器,并已进行了广泛的临床测试。重要的是,arimoclomol有效地穿过了血脑屏障,为靶向GD的神经系统表现提供了机会,而GD无需进行任何改善疾病的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号